Oncimmune Holdings PLC on Thursday highlighted its ability to secure repeat business from ‘top 10 pharma companies’.

The Leeds, England-based autoantibody profiling research services to pharmaceutical and biotechnology industry to enable delivery of precision medicine said it signed three new contracts with a total value of £340,000 since its last trading update on September 9.

However, Oncimmune added that while the new contracts do not mean a raised outlook for the current financial year 2025 ending August 31, they underpinned market expectations.

Chief Executive Officer Martin Gouldstone said: ‘I am pleased to see that our relentless focus on the commercial side of the business continues to bear fruit. These new wins with existing Top 10 Pharma customers keeps us on track to be a profitable business in FY2025.’

Oncimmune shares were 2.1% higher at 15.83 pence each on Thursday afternoon in London.

Copyright 2024 Alliance News Ltd. All Rights Reserved.